Open Orphan

Open Orphan PLC targeting 'value creation and rapid scale-up'

Proactive Research analyst Emma Ulker discusses the opportunity with Open Orphan PLC (LON:ORPH).

She says the firm's targeting value creation and rapid scale-up via acquisitions in the orphan and rare drugs market - a space which is growing at around 11% a year.

Ulker adds they're looking to combine a number of smaller consultancies focused on the orphan and rare disease space, extracting both top-line and cost synergies.

Quick facts: Open Orphan

Price: £0.06

Market: AIM
Market Cap: £16.26 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan named herein, including the promotion by the Company of Open Orphan in any Content on the Site, the Company receives from said...



Full interview: Open Orphan's Maurice Treacy talks genomics and its health...

Open Orphan PLC's (LON:ORPH) chief commercial officer Maurice Treacy caught up with Proactive London's Andrew Scott for a chat on their health databank. Also up for discussion is how Genomic Orphan Health data will work and how important GDPR is to ensure privacy and security.

2 days, 20 hours ago

2 min read